CJC-1295
A GHRH analog commonly discussed in growth-hormone optimization circles and research-market peptide stacks.
Also referenced as: Drug Affinity Complex CJC-1295
Also appears in: Muscle Growth
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary lane: Growth Hormone. Also surfaces under Muscle Growth for browsing and discovery.
Drug Affinity Complex CJC-1295
No FDA label signal · 1 trials · 26 PubMed results
What CJC-1295 is
CJC-1295 is a synthetic analog of growth hormone-releasing hormone. It is often discussed in research-market contexts as a way to stimulate endogenous growth-hormone signaling rather than supplying growth hormone directly.
Why it matters
It sits near the center of the “GH secretagogue” conversation, especially when paired in discussion with compounds like ipamorelin. That makes it a useful profile for understanding the difference between growth-hormone pathway signaling and actual FDA-approved hormone medicines.
Regulatory context
CJC-1295 is not FDA-approved as a peptide medicine in the United States. Most discussion around it belongs to the research-market or performance-oriented side of the peptide world.
Practical reading note
This is one of the clearest examples of a peptide that gets discussed as if it were a routine wellness therapy even though its real regulatory footing is much looser.